within Pharmacolibrary.Drugs.ATC.B;

model B01AC10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.18333333333333332,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Indobufen is a non-steroidal anti-inflammatory drug (NSAID) with antiplatelet properties, primarily used for the prevention of thromboembolic disorders such as in patients with coronary artery disease and after vascular surgery. It acts as a reversible inhibitor of platelet cyclooxygenase and is approved and used in some countries, particularly in Europe, though it is not universally available worldwide.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on studies in healthy adult volunteers (both male and female), typically after single oral doses.</p><h4>References</h4><ol><li><p>Wiseman, LR, et al., &amp; Buckley, MM (1992). Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease. <i>Drugs</i> 44(3) 445–464. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199244030-00009&quot;>10.2165/00003495-199244030-00009</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1382938/&quot;>https://pubmed.ncbi.nlm.nih.gov/1382938</a></p></li><li><p>Glówka, FK, et al., &amp; Zapalski, S (2001). Steady-state pharmacokinetics of indobufen enantiomers in patients with obliterative atherosclerosis. <i>Chirality</i> 13(6) 308–312. DOI:<a href=&quot;https://doi.org/10.1002/chir.1036&quot;>10.1002/chir.1036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11370020/&quot;>https://pubmed.ncbi.nlm.nih.gov/11370020</a></p></li><li><p>Savazzi, GM, et al., &amp; Borghetti, A (1986). Effect of age on the pharmacokinetics of indobufen. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 24(5) 265–269. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3733275/&quot;>https://pubmed.ncbi.nlm.nih.gov/3733275</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC10;
